Vonoprazan, a medication used to treat acid-related disorders such as erosive esophagitis and H. pylori infections, is now available in Nepal with brand name VONOPRAZ. The 58th meeting of the Drug Advisory Committee recently decided to authorize the use of this medicine in the country. Following an application by the Nepali pharmaceutical company Biogain Remedies Pvt. Ltd. in 2023, the Department of Drug Administration (DDA) has officially approved its production after three years.
Key features and benefits of Vonoprazan:
Superior to Traditional PPIs: Unlike traditional Proton Pump Inhibitors (like Omeprazole or Pantoprazole), Vonoprazan works faster, provides long-lasting acid control, and its effectiveness does not depend on meal timings.
High Healing Rate: Various studies have shown a high healing rate for erosive esophagitis. It has also been successful in improving symptoms in patients who did not respond well to traditional PPIs.
Effectiveness against H. pylori: Vonoprazan-based therapy has proven more successful than traditional treatments for H. pylori infections, particularly in cases involving antibiotic resistance.